Nuvation Bio Inc.
Heterocyclic compounds as adenosine antagonists

Last updated:

Abstract:

5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

Status:
Grant
Type:

Utility

Filling date:

17 Jan 2020

Issue date:

19 Apr 2022